Abstract
Summary:#We present a patient with juvenile neuronal ceroid lipofuscinosis who developed a neuroleptic malignant syndrome when treated for hallucinations with a very low dose of risperidone, an atypical neuroleptic medication with usually few extrapyramidal side-effects. The loss of dopaminergic neurons in this condition may make these patients more vulnerable to this severe adverse effect.
Similar content being viewed by others
REFERENCES
Aberg L, Liewendahl K, Niukkinen P, Autti T, Rinne JO, Santavuori P (2000) Decreased striatal dopamine transporter density in JCNL patients with parkinsonian symptoms. Neurology 54: 1069–1074.
Baldessarini RJ (1996) Drugs and the treatment of psychiatric disorders. Psychosis and anxiety. In Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th edn. New York: McGraw-Hill 399–430.
Boustany RM (1992) Neurology of the neuronal ceroid-lipofuscinoses: late infantile and juvenile types. Am J Med Genet 42: 533–555.
Munroe PB, Mitchison HM, O'Rawe AM, et al (1997) Spectrum of mutations in the Batten disease gene, CLN3. Am J Hum Genet 61: 310–316.
Walkley SU, March PA, Schroeder CE, Wurzelmann S, Jolly RD (1995) Pathogenesis of brain dysfunction in Batten disease. Am J Med Genet 57: 196–203.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Vercammen, L., Buyse, G.M., Proost, J.E.F. et al. Neuroleptic malignant syndrome in juvenile neuronal ceroid lipofuscinosis associated with low-dose risperidone therapy. J Inherit Metab Dis 26, 611–612 (2003). https://doi.org/10.1023/A:1025916518457
Issue Date:
DOI: https://doi.org/10.1023/A:1025916518457